Moreover, ␤-myosin heavy chain (␤-MHC) and atrial natriuretic factor (ANF) mRNA expression was significantly elevated in MA-ISO. These results demonstrate that adult rats develop greater impairments in systolic performance than younger rats when exposed to chronic catecholamine excess. Reduced contractile reserve may result from calcium dysregulation, increased caspase-3 activity, or increased ␤-MHC and ANF expression. Although several studies report agerelated declines in systolic performance in older and senescent animals, the present study demonstrates that catecholamine excess induces reductions in systolic performance significantly earlier in life. cardiac hypertrophy; isoproterenol IT IS WELL ESTABLISHED THAT older patients, when subjected to increases in sympathetic drive and/or afterload, develop heart failure (HF) more frequently compared with younger populations (21, 23, 33, 36) . Additionally, incidences of cardiovascular disease, cardiac hypertrophy, and HF are more prevalent with advancing age (7, 8) . The aging heart, in both humans and rats, becomes functionally impaired at the level of the organ and the cardiomyocyte (7, 21, 33) . Age-related decreases in the contractile reserve of the heart are associated with left ventricular (LV) hypertrophy, activation of proapoptotic enzymes, and calcium cycling defects within the myocyte (2, 9, 19, 22) . The underlying cause of age-related declines in systolic performance are not completely understood but may include the following: a decrease in crucial Ca 2ϩ handling proteins such as sarco(endo)plasmic reticulum Ca 2ϩ -ATPase-2a (SERCA2a), a shift in myosin gene expression that results in higher levels of low-velocity ␤-myosin heavy chain (␤-MHC), or an increase in caspase activity. (1, 7-10, 21, 22, 33). Chronic administration of the nonselective ␤-receptor agonist isoproterenol (ISO) is an experimental model of cardiac hypertrophy that is characterized by decreases in cardiac contractility, disruptions in intracellular Ca 2ϩ handling, and increases in cardiomyocyte apoptosis and necrosis (6, 32, 51). Chronic increases sympathetic activity and the sustained elevation of circulating catecholamines are known to worsen systolic function and to decrease contractile reserve, whereas ␤-receptor antagonism mitigates the progression of clinical HF (31, 36) .
IT IS WELL ESTABLISHED THAT older patients, when subjected to increases in sympathetic drive and/or afterload, develop heart failure (HF) more frequently compared with younger populations (21, 23, 33, 36) . Additionally, incidences of cardiovascular disease, cardiac hypertrophy, and HF are more prevalent with advancing age (7, 8) . The aging heart, in both humans and rats, becomes functionally impaired at the level of the organ and the cardiomyocyte (7, 21, 33) . Age-related decreases in the contractile reserve of the heart are associated with left ventricular (LV) hypertrophy, activation of proapoptotic enzymes, and calcium cycling defects within the myocyte (2, 9, 19, 22) . The underlying cause of age-related declines in systolic performance are not completely understood but may include the following: a decrease in crucial Ca 2ϩ handling proteins such as sarco(endo)plasmic reticulum Ca 2ϩ -ATPase-2a (SERCA2a), a shift in myosin gene expression that results in higher levels of low-velocity ␤-myosin heavy chain (␤-MHC), or an increase in caspase activity. (1, 7-10, 21, 22, 33) . Chronic administration of the nonselective ␤-receptor agonist isoproterenol (ISO) is an experimental model of cardiac hypertrophy that is characterized by decreases in cardiac contractility, disruptions in intracellular Ca 2ϩ handling, and increases in cardiomyocyte apoptosis and necrosis (6, 32, 51) . Chronic increases sympathetic activity and the sustained elevation of circulating catecholamines are known to worsen systolic function and to decrease contractile reserve, whereas ␤-receptor antagonism mitigates the progression of clinical HF (31, 36) .
A blunted contractile reserve is indicative of decreased myocardial viability and characteristic of human HF (5, 44) . Inotrope-induced increases in [maximum of LV pressure development (ϩdP/dt max )] reflects contractile reserve, and this index is measured to clinically assess a patient's cardiac performance (26, 44) . Cardiac function can often appear normal until subjected to stresses, such as excessive adrenergic stimulation, which reveal underlying impairments (23, 36) . In fact, an ample contractile reserve is predictive of a better prognosis in patients with LV dysfunction at rest (18) .
Because mature adults may have a diminished capacity to respond to cardiac stress compared with those in the growing phase, and because aging and catecholamine excess negatively impact cardiovascular function, the present study was undertaken to determine whether mature adult rats are more susceptible to ISO-induced reductions in contractile reserve than younger adult rats. Previous reports on the effect of aging on cardiovascular function in rats have focused primarily on comparisons between senescent or old (Ͼ20 mo) and mature adult (2-4 mo) animals (1) . These studies have revealed that older rodent hearts have depressed contractility as measured by changes in ϩdP/dt max , and have reduced levels of SERCA2a (1, 13) . While the senescent, aging heart is more susceptible to cardiac insult, little is known concerning the difference in cardiac functional responses between mature adult and young adult rats following chronic catecholamine excess (10, 19) . The present study was conducted in groups of animals not yet expected to demonstrate age-related detriments in myocardial structure or resting function (7, 8) . The animals selected for the present experiments represent precise and distinct stages of development according to the lifespan and growth of this particular species and strain (12). Animals identified as young adults (YA; aged 12 wk at end point) were still in their rapidly growing phase, while those identified as mature adults (MA; aged 18 wk at end point) had reached expected maximal weight when functional measurements were recorded (12). This assertion is supported by the fact that YA animals in the present study experienced a 43% increase in weight, while MA in-creased in weight by only 15%. Over the course of the 3-wk study, YA rats grew from 240 Ϯ 4 g (9 wk old) to 344 Ϯ 7 g (12 wk old), while MA grew from 399 Ϯ 3 g (15 wk old) to 460 Ϯ 5 g (18 wk old).
MATERIALS AND METHODS
Animals. All experimental procedures were carried out in accordance with protocols approved by the Gilead Colorado Institutional Animal Care and Use Committee. Male Sprague-Dawley rats (Charles River Laboratories) were maintained on a standard laboratory diet (Teklad 22-5, 8640) with water ad libitum. Experiments were performed on young adult (YA; aged 9 wk at study inception and aged 12 wk at end point) and mature adult (MA; aged 15 wk at study inception and aged 18 wk at end point). Initial pilot studies established that increases in HR following ISO (0.1 mg/kg sc) were similar in MA and YA (140 Ϯ 15 vs. 150 Ϯ 25 beats/min). Following a 1-wk acclimation period, animals were separated into four weight and age-matched groups: young adults that received daily injections of the vehicle (1% ascorbic acid solution in diH 2O) for 3 wk (YA); young adults that received daily injections of ISO (0.1 mg·kg Ϫ1 ·day Ϫ1 sc) for 3 wk (YA-ISO); mature adult animals that received daily injections of the vehicle for 3 wk (MA); and mature adult animals that received daily injections of ISO (0.1 mg·kg Ϫ1 ·day Ϫ1 sc) for 3 wk (MA-ISO). All animals were weighed daily between 08:00 and 09:30 and dosed immediately thereafter to ensure consistent, weight-dependent administration of drugs and vehicle throughout the study. Animals did not receive injections on the day hemodynamics and cardiac performances were evaluated.
In vivo ventricular and systemic hemodynamics. Anesthesia was induced by inhalation of isofluorane in a closed chamber. Animals were then intubated, and the appropriate plane of anesthesia was maintained during the entire course of the experiment with 2% isofluorane delivered through a vaporizer (model VIP 3000; Matrx, Orchard Park, NY) and carried by 100% oxygen (0.8 l/min). Peak inspiratory pressure was maintained between 12-15 cmH 2O and the ventilation rate was kept at 50 beats/min (Anesthesia Workstation; Hallowell EMC, Pittsfield, MA). A Millar catheter (model SPR-869, Millar Instruments, Houston, TX) was inserted into the right carotid artery and advanced into the left ventricle through the aortic valve. A separate Millar catheter (model SPR-838) was inserted into the right femoral artery and advanced into the abdominal aorta for measurement of systemic hemodynamics. A segment of PE-50 was inserted into the right femoral vein for the infusion of drugs. A rectal thermometer attached to a servo-controlled heating pad (model TC-1000; CWE, Ardmore, PA) was used to maintain body temperature at 37 Ϯ 0.1°C. After allowing for stabilization from surgical preparation, steady-state LV and systemic hemodynamics were recorded on a personal computer using a pressure-volume unit (model MPVS-300; ADInstruments, Colorado Springs, CO). All hemodynamic data were acquired with the ventilator briefly turned off (3-5 s). Tau (Weiss), a time constant of LV pressure decay, was used to assess LV diastolic function. Increases in Tau (Weiss) occur with prolonged relaxation times and are attributed to a reduction in the rate of diastolic removal of cytoplasmic Ca 2ϩ via SERCA2a (22) . PVAN data analysis software (version 3.5; Millar Instruments) was used to analyze all ventricular and systemic hemodynamic data.
Assessment of contractile reserve. The maximum rate of LV pressure development (ϩdP/dt max) following inotrope and/or vehicle infusions was compared with steady-state baseline values for each animal to determine ⌬ϩdP/dt max. The ⌬ϩdP/dtmax accurately reflects systolic performance and was used as an index of contractile reserve (26) . In fact, estimates of ϩdP/dtmax can reveal functional impairments in asymptomatic and mildly symptomatic HF patients who have normal LV performance at rest (16, 28) . Two distinct pharmacological agents were used to assess contractile reserve, and animals were randomly assigned to a given agent prior to study inception. Increasing doses (20, 60 , and then 200 g·kg Ϫ1 ·min Ϫ1 ) of milrinone or digoxin were serially infused (iv) based on dose-response curves previously generated in naïve young and adult animals (data not shown). Due to solubility limitations, lower doses (20 and 60 g·kg Ϫ1 ·min Ϫ1 ) were infused at a rate of 10 l/min per 100 g body wt (e.g., 300 g rat received 30 l/min), while the highest dose of agonist (200 g·kg Ϫ1 ·min Ϫ1 ) was infused at 20 l/min per 100 g body wt. Pilot studies demonstrated that this increment in infusion rate does not elicit effects on ventricular or systemic hemodynamics over the course of a typical experiment. Steady-state ventricular and systemic parameters were recorded prior to infusion of drug. Infusions continued for 10 -15 min, and data were recorded after hemodynamics and ϩdP/dt max were stable.
General experimental protocol. After 3 wk of daily ISO or vehicle administration, a subset of each treatment group was subjected to contractile reserve assessment with either digoxin or milrinone. Cardiac hypertrophy was assessed by calculating the LV index (LVI) for each animal according to the following formula: [weight of LV free wall with septum (mg)/tibia length (mm)]. To control for the potential effects of inotropic agents on biochemical end points, separate groups of rats received either vehicle or ISO for 3 wk prior to being subjected to end point biochemical analysis. To ensure similar disease phenotype, baseline ventricular and hemodynamic parameters, as well as morphologic data (LVI, body wt) were recorded in every animal.
Quantitative real-time PCR. Total RNA was isolated from tissue by using a Ribopure Kit (Ambion, Austin, TX) and 1 g was reverse transcribed using the Superscript III cDNA Synthesis kit (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Quantitative RT-PCR was done on an ABI 7300 real-time PCR instrument (Applied Biosystems, Foster City, CA) using TaqMan universal PCR master mix (Applied Biosystems) following the manufacturer's instructions. Probes and primers were from TaqMan gene expression assay reagents (cat. no. SERCA2A-Rn00568762_m1; Applied Biosystems). Standard curves were generated by serial dilution of cDNA, and relative quantification of target and housekeeping gene levels were done by ABI 7300 instrument algorithm software. Relative levels of target RNA between samples was calculated after normalization with 18S ribosomal RNA (rRNA) gene (cat. no. 4308329).
QuantiGene muliplex assays for mRNA expression. A 10 -30 mg sample of apical LV free wall was homogenized in tissue and cell lysis buffer (Epicentre Technologies, Madison, WI) supplemented with 100 g/ml proteinase K (Panomics, Fremont, CA) for 2 h at 60°C with occasional shaking. Homogenates were then used in the QuantiGene Multiplex Assay (Panomics) by hybridizing specified probe sets according to the manufacturer's instructions. Transcript expression was subsequently measured in a model 200 (Luminex, Austin TX) and relative quantitation of mRNA levels were calculated after normalization against the housekeeping gene hypoxanthine phosphoribosyltransferase.
Caspase activity. A caspase-3 fluorometric assay kit (cat. no. BF1100; R&D Systems, Minneapolis, MN) and a BCA protein assay kit (cat. no. 23235; Thermo Fisher, Rockford, IL) were used in the present study. A tissue lysis buffer containing 1ϫ PBS, 1 mM EDTA, 0.5% Triton X-100, 1ϫ phosphatase inhibitor (cat. no. 78428; Thermo Fisher), and 1 ϫ protease inhibitor (cat. no. 1860932; Thermo Fisher) was prepared. Uniform samples of apical LV free wall were lysed in 500 l of tissue lysis buffer, and BCA assay was performed to determine the total protein concentration. Caspase-3 fluorometric assays were performed in 96-well flat-bottom microplates. The reaction mixture contained 50 l of tissue lysate (200 g total protein), 50 l of assay buffer (2ϫ), and 50 mM of fluorescent substrate. Plates were incubated at 37°C for 1 h and read on a SpectroMax M5e (light excitation at 400 nm with emitted light at collected 505 nm). The results are expressed as fold increase in caspase activity normalized by the control group.
Drugs. (Ϫ)-Isoproterenol hydrochloride, milrinone, digoxin, and (ϩ)-sodium L-ascorbate were obtained from Sigma-Aldrich (St.
Louis, MO). Isoproterenol, milrinone, and ascorbic acid were dissolved in diH 2O, whereas digoxin was dissolved in a solution of 33% methanol and diH2O, which was then diluted to achieve lower doses.
Data analysis and statistics. A one-way ANOVA followed by Bonferroni multiple comparisons test was performed on baseline and end point data to determine the effect of ISO treatment. These results were analyzed on a personal computer (GraphPad Prism version 5.0; GraphPad Software) and presented as means Ϯ SE. A value of P Յ 0.05 was considered statistically significant. Data generated during serial infusions of an inotrope were analyzed using two-way repeatedmeasures ANOVA with a Holm-Sidak post test on a personal computer (SigmaPlot version 11.0; Systat Software) and presented as means Ϯ SE. A value of P Յ 0.05 was considered statistically significant.
RESULTS
Effect of chronic ISO administration on baseline cardiac performance and hemodynamics. The effect of chronic ISO administration (0.1 mg/kg sc, for 21 days) on baseline ϮdP/dt (mmHg ϫ s Ϫ1 ), Tau (Weiss; ms), heart rate (beats/min), and mean arterial pressure (MAP; mmHg) was investigated in YA and MA rats, and these data are summarized in Figs. 1 and 2. There was no difference in baseline contractility between YA-ISO, MA, and MA-ISO rats. However, YA rats had significantly greater positive and negative basal dP/dt max (6, (Fig. 2A) . Chronic ISO significantly increased LV relaxation time in both YA-ISO and MA-ISO compared with their age-matched vehicle controls (12.89 Ϯ 0.51, 12.07 Ϯ 0.32, respectively) ( Fig. 2A ). There were no differences in basal heart rate or MAP between treatment groups (Figs. 2, B-C) .
Effect of chronic ISO administration on responses to mechanistically distinct inotropic agents. Responses to infusions of milrinone were investigated in young and mature adult animals following chronic ISO administration (Fig. 3, A-B) . ISO treatment did not significantly influence the effect of serial milrinone infusions (20 - ) doses of milrinone were not different (P ϭ 0.068 and P ϭ 0.658, Fig. 1 . Baseline contractility of all animals (YA, YA-ISO, MA, and MA-ISO) prior to assessment of contractile reserve. Positive and negative dP/dtmax were diminished in all groups compared with YA controls. YA, young adults; MA, mature adults; ISO, isoproterenol; dP/dtmax, maximum of left ventricular pressure development. Data are the means Ϯ SE (1-way ANOVA followed by a Bonferroni multiple comparisons test; n ϭ 9 -14). *P Ͻ 0.05 vs. vehicletreated YA rats. Fig. 2 . Baseline values for Tau (Weiss) (A), heart rate (B), and mean arterial pressure (C) in all animals (YA, YA-ISO, MA, and MA-ISO) prior to assessment of contractile reserve. Tau was elevated in YA-ISO and MA-ISO compared with their vehicle-treated controls. There were no differences in heart rate (HR) or mean arterial pressure (MAP) across groups. Data are the means Ϯ SE (one-way ANOVA followed by a Bonferroni multiple comparisons test; n ϭ 5-9). *P Ͻ 0.05 vs. age-matched controls.
respectively) compared with YA (Fig. 3A) . In contrast, the effect of serial milrinone infusions (20 -200 g·kg Ϫ1 ·min Ϫ1 ) on changes in ϩdP/dt max was attenuated in MA-ISO compared with vehicle-treated, age-matched controls (P ϭ 0.001) (Fig.  3B) . Moreover, increases in ϩdP/dt max were decreased at every dose of milrinone (20, 60, 200 g·kg Ϫ1 ·min Ϫ1 ) (P ϭ 0.039, P ϭ 0.001, and P Ͻ 0.001, respectively.) in MA-ISO compared with MA controls (Fig. 3B) . Milrinone (20 -200 g·kg Ϫ1 ·min Ϫ1 ) increased ϩdP/dt max similarly in YA and MA controls (P Ͼ 0.5) (Fig. 3, A-B) . HR, SAP, and MAP were similar across groups following the infusion of milrinone (Table 1) .
Responses to infusions of increasing doses of digoxin (20 -200 g·kg Ϫ1 ·min Ϫ1 ) were investigated in young adult and mature adult animals following chronic ISO administration (Fig. 3, C-D) . ISO treatment did not significantly influence the effect of serial digoxin infusions (20 -200 g·kg Ϫ1 ·min Ϫ1 ) on increases in ϩdP/dt max in YA-ISO compared with YA controls (P ϭ 0.194) (Fig. 3C) ) on increases in ϩdP/dt max in MA-ISO compared with MA controls (P ϭ 0.01) (Fig. 3D) . Moreover, increases in ϩdP/dt max were diminished at every dose of digoxin (20, 60, 100 g·kg Ϫ1 ·min Ϫ1 ) (P Ͻ 0.001, P ϭ 0.042, and P Ͻ 0.036, respectively) in MA-ISO compared with MA (Fig. 3D) . Digoxin infusions (20 -200 g·kg Ϫ1 ·min Ϫ1 iv) induced similar increases in ϩdP/dt max in YA and MA (P Ͼ 0.5) (Fig. 3, C-D) . HR, SAP, and MAP were similar across groups following the infusion of digoxin ( Table 1) .
Effect of chronic ISO administration on LVI. The effects of chronic ISO administration on cardiac hypertrophy are shown in Fig. 4 . Chronic ISO administration induced significant increases in LV hypertrophy (LVI) in both YA-ISO and MA-ISO rats compared with their age-matched vehicle controls (YA: 24.6 Ϯ 1.0 vs. 20.2 Ϯ 0.8; MA: 28.0 Ϯ 0.6 vs. 21.2 Ϯ 0.5) (P Ͻ 0.05) (Fig. 4) . However, ISO induced a greater increase in LVI in MA-ISO compared with YA-ISO rats (33 Ϯ 3% vs. 22 Ϯ 5% increase) (Fig. 4) . ) produced similar responses in YA-ISO and YA animals (P ϭ 0.194; 2-way repeated-measures ANOVA followed by Holm-Sidak; n ϭ 4 -7) . D: contractile response to digoxin (20 -200 g·kg Ϫ1 ·min Ϫ1 ) was significantly attenuated in MA-ISO compared with MA controls (P ϭ 0.01; 2-way repeated-measures ANOVA followed by Holm-Sidak; n ϭ 4 -7).*P Ͻ 0.05 vs. same dose in vehicle-treated animals, ‡P Ͻ 0.05 for effect of treatment (ISO) on the response to serial inotrope infusion.
Effects of chronic ISO and age on biochemical indices of LV contractility and pathological remodeling.
Quantitative PCR was used to investigate changes in LV expression of SERCA2a (Fig. 5A) . MA had reduced SERCA2a mRNA expression compared with YA rats (91 Ϯ 18 vs. 161 Ϯ 11 arbitrary units, 18S corrected) (P Ͻ 0.05). ISO treatment diminished SERCA2a mRNA expression in both YA-ISO and MA-ISO animals compared with their respective agematched vehicle controls (YA: 82 Ϯ 15 vs. 161 Ϯ 11; MA: 36 Ϯ 4 vs. 91 Ϯ 18) (P Ͻ 0.05). Furthermore, MA-ISO rats had reduced SERCA2a mRNA expression compared with YA-ISO rats (36 Ϯ 4 vs. 82 Ϯ 15) (P Ͻ 0.05) (Fig. 5A) . The effect of ISO on caspase-3 activity in LV tissue was also investigated (Fig. 5B ). There were no differences in caspase activity detected among YA, YA-ISO, and MA rats. In contrast, chronic ISO administration increased caspase activity 1.34-fold in MA-ISO compared with MA controls (P Ͻ 0.05) (Fig. 5B) .
The effect of chronic ISO administration on LV ␤-MHC, atrial natriuretic factor (ANF), and collagen1a mRNA expression was investigated and compared among all groups (Fig. 6, A-C) . ISO increased ␤-MHC mRNA expression in MA-ISO compared with age-matched controls (P Ͻ 0.05) (Fig. 6A) . Chronic ISO administration did not increase ANF mRNA expression in YA-ISO compared with YA. However, ISO increased ANF mRNA expression in MA-ISO rats compared with MA rats (2,670 Ϯ 981 vs. 182 Ϯ 42) (P Ͻ 0.05) (Fig. 6B) . ISO induced similar increases in collagen1a mRNA expression in YA-ISO and MA-ISO animals compared with their respective age-matched vehicle controls (Fig. 6C) . Values are means Ϯ SE for YA, young adult group; MA, mature adult group; ISO, isoproterenol added. Baseline values for heart rate (HR), systolic arterial pressure (SAP), and mean arterial pressure (MAP) were not different across all groups (n ϭ 8 -14); these values were also not different following the infusions of milrinone (n ϭ 4 -7) or digoxin (n ϭ 4 -7); 1-way ANOVA followed by a Bonferroni multiple comparisons test. 
DISCUSSION
The present results demonstrate that nonsenescent, mature adult rats (18 wk) are more susceptible to the deleterious effects of chronic catecholamine excess than younger animals (12 wk). The present findings suggest that abnormal myocardial responses to stress can be detected in animals at an earlier age than has previously been demonstrated (18, 37, 55) . Mature adult rats displayed greater reductions in contractile reserve following chronic ISO administration and closely resembled a HF phenotype characterized by a dysregulation in Ca 2ϩ handling, a reengagement of the fetal gene program, and an activation of a key apoptotic enzyme. The present study examined contractile reserve, indexed by changes in ϩdP/dt max in response to mechanistically distinct inotropes to reveal systolic impairments in animals that have normal cardiac function at baseline (1, 26, 37) . Differences in systolic performance were observed even though milrinone-and digoxininduced changes in HR, and hemodynamics were similar across groups. This observation indicates that the present results are due to innate cardiac factors and are not due to agonist effects on chronotropy, loading conditions, or systemic hemodynamics (55) .
The present study was designed to investigate whether MA were more sensitive to the effects of chronic catecholamine excess than YA, but the present data do not address whether or not differences in acute cardiovascular responses to ISO exists or develops among the ages of animals used in the present study. We did observe similar acute increases in HR in YA and MA animals following acute ISO administration (pilot studies), but it is possible that differing effects of acute ISO on blood pressure and HR may have developed and contributed to the present results. Potential studies designed to characterize differences in acute cardiovascular responses to ISO over time are severely limited by the fact that ISO induces ␤-receptor dysfunction, regardless of age (18, 21, 32) . In the future, longitudinal studies using radiotelemetry in conscious animals will be needed to systematically determine whether acute responsiveness to ISO changes over time and influences subsequent outcomes. Additionally, whether or not the observed changes contribute to decreases in cardiovascular function during postmaturational aging or senescence is beyond the scope of the present study.
In vivo and isolated heart studies comparing mature and senescent animals have established that contractile reserve along with the ability of the myocardium to adapt to added stress diminishes with advancing age (1, 10, 36, 37) . ISO has also been demonstrated to cause greater impairments of contractile responses in hearts from rats aged 28 -30 mo compared with hearts from rats aged 6 -8 mo (25) . Although age-related declines in cardiovascular function are well documented among mature adult (8 -20 wk) , old (Ͼ80 wk), and senescent rodents (Ͼ100 wk), these differences have not previously been reported to occur earlier in life (15, 19, 21, 23, 34, 46, 48, (53) (54) (55) .
Because ␤-receptor dysfunction is known to occur in models of catecholamine excess, the present study utilized clinically relevant inotropic agents that elicit effects independent of direct ␤-receptor activation (18, 21, (32) (33) (34) 41) . This strategy minimized the confounding effects of ␤-receptor desensitization and/or downregulation that likely influenced previous assessments of contractile reserve in this model (19, 33, 34, 39, 41) . Milrinone acts distally to the ␤-receptor, inhibiting the phosphodiesterase (type III) that specifically degrades cAMP (41) . It is unclear whether ␤-receptor dysfunction can alter the availability of cAMP in this model; however, many studies have demonstrated efficacy of milrinone in animal and human HF (24, 41) . Digoxin has a long history of clinical use for the treatment of congestive HF (3, 4, 11, 50) . This cardiac glycoside promotes myocardial Ca 2ϩ entry which increases cardiac contractility mainly through the inhibition of the sarcolemmal Na
). There is evidence that inotropic responses to cardiac glycosides can be reduced in models of cardiac hypertrophy and dysfunction. The mechanisms for this effect are controversial but may be explained by underlying Ca 2ϩ handling defects within the cardiomyocytes (3, 4, 11, 27, 50) .
There are several potential molecular mechanisms to explain the differing levels of systolic impairment in mature adult and young adult rats following chronic catecholamine excess. Previous reports demonstrating systolic impairments induced by aging or chronic ISO administration implicate factors such as: dysregulations in Ca 2ϩ handling, inductions of the fetal gene program, and/or increases in caspase activity (1, 8, 10, 15, 22) . Therefore, we conducted an initial survey of these factors in an attempt to identify pathways that may be involved with ISOinduced decreases in contractile reserve.
Disruption in Ca 2ϩ cycling is a critical mechanism underlying impairments in the contractile function of the heart, and it is well known that the aging heart is more susceptible to Ca 2ϩ overload (22, 29) . In the present experiments, chronic ISO decreased SERCA2a mRNA expression in both YA and MA rats. However, expression in MA-ISO was significantly reduced compared with the YA-ISO group. These changes would be expected to decrease the amplitude of Ca 2ϩ transients and impair systolic force (22) . These data are in agreement with studies demonstrating age-related and ISO-induced decreases in SERCA2a mRNA expression, and with the notion that ␤-receptor stimulation can reveal underlying impairments in Ca 2ϩ handling (1, 2, 15, 40) . Present evidence of decreased SERCA2a mRNA expression following chronic ISO administration is supported by functional data showing increases in Tau (Weiss). The present findings are in agreement with studies demonstrating that Tau is prolonged in aging hearts and studies demonstrating that SERCA2a mRNA begins to decline in the rodent at 16 wk of age (29, 34, 43) . There are other potential detriments in Ca 2ϩ handling that could explain the observed differences that were not addressed in the present study. The L-type Ca 2ϩ channel, the ryanodine receptor, and phosphatase-1 are involved in maintaining normal Ca 2ϩ regulation and have been shown to be altered in various models of systolic impairment (37) . However, SERCA2a has been identified as an initial Ca 2ϩ handling protein affected by aging and the aim of the present study was to evaluate changes expected to occur early in the aging process (1, 23) .
Consistent with previous reports, the present study demonstrates significant LV hypertrophy following chronic ISO administration. The expression of ␤-MHC and ANF, maladaptive hypertrophy markers known to be elevated in models of HF and in humans with heart disease, were increased in MA-ISO compared with YA-ISO rats (13, 53, 17, 52) . Similar agerelated differences in pathological gene expression have been noted between mature adult and senescent rodents (33, 53, 20) . These biochemical differences could explain, in part, the functional cardiac impairments reported in the present study. It is known that small changes in the ␤-MHC content of the myocardium can induce dramatic changes in function (33, 52) . This gene is reciprocally expressed with the more contractile ␣-MHC and an increase in ␤-MHC expression alone has been demonstrated to directly depress cardiac contractile function (20) . The present results are consistent with reports that ANF expression increases with the development of cardiac hypertrophy and with reports of ISO-induced increases in ANF expression (13, 17, 38, 39) .
ISO-induced hypertrophy and human HF are often accompanied by evidence of apoptosis and increased caspase-3 (36, 38, 47) . Caspase-3 activity increased in MA-ISO and was not altered in YA-ISO, supporting the idea that nonsenescent animals are more vulnerable to injury and stress than their younger counterparts. This finding is consistent with a previous study showing that caspase-3 overexpression depresses cardiac function in mice, and with a report that caspase-3 expression is elevated in a dog model of HF (14, 45) . An in vitro study demonstrated that caspase-3 activation leads to a reduction of contractile reserve in LV cardiomyocytes (30) . Additionally, pharmacological inhibition of caspase-3 improved postischemic contractile recovery in the isolated rat heart (49) . The present in vivo results, along with data from several models of cardiovascular injury, support the notion that caspase activation plays a major role in the development of contractile dysfunction (9, 30, 45, 49) . The precise mechanisms of caspase-3-induced reductions in systolic performance are uncertain but may involve perturbations in Ca 2ϩ homeostasis or direct effects on the contractile proteins of the sarcomere (9, 47, 49) .
Perspectives and Significance
This study provides, to our knowledge, the first demonstration that nonsenescent, adult rats (18 wk) have a greater reduction in contractile reserve following chronic, repeated bouts of catecholamine excess than younger animals (12 wk). Although several studies report age-related declines in cardiac performance at both the functional and molecular level in senescent animals, the present data suggest that small differences in age can influence cardiovascular adaptations to stress. The present study demonstrates, through the use of mechanistically distinct inotropes, that the detrimental interaction between age and catecholamine excess on the ability to respond to cardiac demand can be detected early in life. Greater impairments in contractile reserve were associated with decreases in SERCA2a expression, increases in ␤-MHC and ANF expression, and increases in caspase activity. Future investigations are required to further elucidate the interaction between aging and the regulation and relative contribution of these maladaptive processes.
